MASLD, basically a progression of non-alcoholic fatty liver disease. I have been dealing with MASLD, and F3 liver fibrosis, and have changed a lot of my relationship with food. Too close to cirrhosis...so I made cuts from the diet. Especially sugar, empty carbs, fatty fried foods. Docs wanted to put me on the GLP-1s, but I wanted to take some matters in my own hands first. I am down almost 30lbs.
Now I think its time for me to try some CBD/CBG isolate. You guys know any of the good brands?
Check out this info, I tried to summarize it, and add the reference links
-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Recent research published in the British Journal of Pharmacology in March 2026 suggests that two non-psychoactive cannabis compounds, Cannabidiol (CBD) and Cannabigerol (CBG), may help reverse metabolic dysfunction-associated steatotic liver disease (MASLD).

The study, led by researchers at the Hebrew University of Jerusalem, identified a novel mechanism called "metabolic remodeling" that allows these compounds to reduce liver fat and improve metabolic health.
Key Mechanisms of Action
According to the ScienceDaily report, these compounds support the liver through two primary processes:
Comparison of CBD and CBG
While both compounds showed benefits, the study noted specific differences in their effectiveness:
Current Status and Limitations
Despite these promising results in experimental models, researchers emphasize the following:
Now I think its time for me to try some CBD/CBG isolate. You guys know any of the good brands?
Check out this info, I tried to summarize it, and add the reference links
-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Recent research published in the British Journal of Pharmacology in March 2026 suggests that two non-psychoactive cannabis compounds, Cannabidiol (CBD) and Cannabigerol (CBG), may help reverse metabolic dysfunction-associated steatotic liver disease (MASLD).

The study, led by researchers at the Hebrew University of Jerusalem, identified a novel mechanism called "metabolic remodeling" that allows these compounds to reduce liver fat and improve metabolic health.
Key Mechanisms of Action
According to the ScienceDaily report, these compounds support the liver through two primary processes:
- Energy Buffering: They increase levels of phosphocreatine, a high-energy molecule that acts like a "backup battery" for the liver. This helps the organ maintain function even under the stress of a high-fat diet.
- Cellular Cleanup: They restore the activity of enzymes called cathepsins, which act as "cleaning crews" within the cell's recycling centers (lysosomes). This process enables the liver to break down and clear out harmful lipids like triglycerides and ceramides.
Comparison of CBD and CBG
While both compounds showed benefits, the study noted specific differences in their effectiveness:
- CBG (Cannabigerol): Showed more robust results in reducing total body fat mass, lowering "bad" LDL cholesterol, and improving insulin sensitivity.
- CBD (Cannabidiol): Effectively stabilized blood sugar and improved glucose management, but was slightly less potent than CBG in certain metabolic markers.
Current Status and Limitations
Despite these promising results in experimental models, researchers emphasize the following:
- Preclinical Stage: The findings were observed in a controlled experimental environment (mice) and have not yet been fully validated in large-scale human clinical trials.
- Non-Psychoactive: Unlike THC, these compounds do not produce a "high," which makes them more viable candidates for long-term medical development.
- Scientific Gaps: Other recent reviews, such as those in JAMA, note that while results are encouraging, high-quality clinical data for many cannabinoid therapies is still limited.